2.54
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
Low
1.98
High
6.77
Best deals to access real time data! |
CHART Trader
Monthly Subscription
for only
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
Small Cap Basic
Monthly Subscription
for only
|
VAT not included
|
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Eloxx Pharmaceuticals Inc | ELOX | NASDAQ | Common Stock |
Price Change | Change Percent | Stock Price | Last Traded ![]() |
|
---|---|---|---|---|
0.00 | 0.0% | 2.54 | 04:00:00 |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.54 |
Bid Price | Ask Price | Spread | News | |
---|---|---|---|---|
2.39 | 3.50 | 1.11 | - | - |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
- | 0 | $ 2.54 | USD |
Eloxx Pharmaceuticals Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 101.99M | 40.15M | 28.27M | $ - | $ - | -1.34 | -4.00 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | 0.00% | - | - |
Eloxx Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ELOX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.99 | 3.12 | 2.52 | 2.67 | 114,337 | -0.45 | -15.05% |
1 Month | 3.73 | 3.90 | 2.52 | 3.12 | 107,343 | -1.19 | -31.9% |
3 Months | 3.96 | 4.98 | 2.52 | 3.67 | 100,025 | -1.42 | -35.86% |
6 Months | 2.79 | 6.77 | 2.39 | 3.80 | 149,499 | -0.25 | -8.96% |
1 Year | 2.09 | 6.77 | 1.98 | 3.50 | 122,753 | 0.45 | 21.53% |
3 Years | 10.35 | 24.60 | 1.44 | 7.36 | 121,049 | -7.81 | -75.46% |
5 Years | 10.35 | 24.60 | 1.44 | 7.36 | 121,049 | -7.81 | -75.46% |
Eloxx Pharmaceuticals Description
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel ribonucleic acid (RNA)-modulating drug candidates that are formulated to treat rare and ultra-rare premature stop codon diseases. The ELX-02, the company's lead investigational drug product candidate, is a small molecule designed to restore the production of full-length functional proteins. The ELX-02, is in the early stages of clinical development for systemic administration for cystic fibrosis and cystinosis. |